

# Global Vasomotor Symptoms Treatment Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/GB3FB2364790EN.html>

Date: January 2024

Pages: 134

Price: US\$ 3,200.00 (Single User License)

ID: GB3FB2364790EN

## Abstracts

### Report Overview

This report provides a deep insight into the global Vasomotor Symptoms Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Vasomotor Symptoms Treatment Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Vasomotor Symptoms Treatment market in any manner.

### Global Vasomotor Symptoms Treatment Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding

the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Bayer AG

Fervent Pharmaceuticals, LLC

Astellas Pharma Inc.

Frazier Healthcare Partners

Mitsubishi Tanabe Pharma Corporation

Eli Lilly and Company

AbbVie Inc.

AMAG Pharmaceuticals Inc.

Emcure Pharmaceuticals Limited

Merck & Co., Inc.

Novartis AG

Novo Nordisk A/S

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

Market Segmentation (by Type)

Hormonal Therapies

Non-Hormonal Therapies

Others

Market Segmentation (by Application)

Clinic

Hospital

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Vasomotor Symptoms Treatment Market

Overview of the regional outlook of the Vasomotor Symptoms Treatment Market:

#### Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning

recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

### Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

### Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Vasomotor Symptoms Treatment Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the

industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

## Contents

### **1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE**

1.1 Market Definition and Statistical Scope of Vasomotor Symptoms Treatment

1.2 Key Market Segments

1.2.1 Vasomotor Symptoms Treatment Segment by Type

1.2.2 Vasomotor Symptoms Treatment Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

### **2 VASOMOTOR SYMPTOMS TREATMENT MARKET OVERVIEW**

2.1 Global Market Overview

2.1.1 Global Vasomotor Symptoms Treatment Market Size (M USD) Estimates and Forecasts (2019-2030)

2.1.2 Global Vasomotor Symptoms Treatment Sales Estimates and Forecasts (2019-2030)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

### **3 VASOMOTOR SYMPTOMS TREATMENT MARKET COMPETITIVE LANDSCAPE**

3.1 Global Vasomotor Symptoms Treatment Sales by Manufacturers (2019-2024)

3.2 Global Vasomotor Symptoms Treatment Revenue Market Share by Manufacturers (2019-2024)

3.3 Vasomotor Symptoms Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Vasomotor Symptoms Treatment Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Vasomotor Symptoms Treatment Sales Sites, Area Served, Product Type

3.6 Vasomotor Symptoms Treatment Market Competitive Situation and Trends

3.6.1 Vasomotor Symptoms Treatment Market Concentration Rate

3.6.2 Global 5 and 10 Largest Vasomotor Symptoms Treatment Players Market Share

by Revenue

3.6.3 Mergers & Acquisitions, Expansion

## **4 VASOMOTOR SYMPTOMS TREATMENT INDUSTRY CHAIN ANALYSIS**

4.1 Vasomotor Symptoms Treatment Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

## **5 THE DEVELOPMENT AND DYNAMICS OF VASOMOTOR SYMPTOMS TREATMENT MARKET**

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

## **6 VASOMOTOR SYMPTOMS TREATMENT MARKET SEGMENTATION BY TYPE**

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Vasomotor Symptoms Treatment Sales Market Share by Type (2019-2024)

6.3 Global Vasomotor Symptoms Treatment Market Size Market Share by Type (2019-2024)

6.4 Global Vasomotor Symptoms Treatment Price by Type (2019-2024)

## **7 VASOMOTOR SYMPTOMS TREATMENT MARKET SEGMENTATION BY APPLICATION**

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Vasomotor Symptoms Treatment Market Sales by Application (2019-2024)

7.3 Global Vasomotor Symptoms Treatment Market Size (M USD) by Application (2019-2024)

## 7.4 Global Vasomotor Symptoms Treatment Sales Growth Rate by Application (2019-2024)

# **8 VASOMOTOR SYMPTOMS TREATMENT MARKET SEGMENTATION BY REGION**

## 8.1 Global Vasomotor Symptoms Treatment Sales by Region

### 8.1.1 Global Vasomotor Symptoms Treatment Sales by Region

### 8.1.2 Global Vasomotor Symptoms Treatment Sales Market Share by Region

## 8.2 North America

### 8.2.1 North America Vasomotor Symptoms Treatment Sales by Country

#### 8.2.2 U.S.

#### 8.2.3 Canada

#### 8.2.4 Mexico

## 8.3 Europe

### 8.3.1 Europe Vasomotor Symptoms Treatment Sales by Country

#### 8.3.2 Germany

#### 8.3.3 France

#### 8.3.4 U.K.

#### 8.3.5 Italy

#### 8.3.6 Russia

## 8.4 Asia Pacific

### 8.4.1 Asia Pacific Vasomotor Symptoms Treatment Sales by Region

#### 8.4.2 China

#### 8.4.3 Japan

#### 8.4.4 South Korea

#### 8.4.5 India

#### 8.4.6 Southeast Asia

## 8.5 South America

### 8.5.1 South America Vasomotor Symptoms Treatment Sales by Country

#### 8.5.2 Brazil

#### 8.5.3 Argentina

#### 8.5.4 Columbia

## 8.6 Middle East and Africa

### 8.6.1 Middle East and Africa Vasomotor Symptoms Treatment Sales by Region

#### 8.6.2 Saudi Arabia

#### 8.6.3 UAE

#### 8.6.4 Egypt

#### 8.6.5 Nigeria

#### 8.6.6 South Africa

## 9 KEY COMPANIES PROFILE

### 9.1 Bayer AG

- 9.1.1 Bayer AG Vasomotor Symptoms Treatment Basic Information
- 9.1.2 Bayer AG Vasomotor Symptoms Treatment Product Overview
- 9.1.3 Bayer AG Vasomotor Symptoms Treatment Product Market Performance
- 9.1.4 Bayer AG Business Overview
- 9.1.5 Bayer AG Vasomotor Symptoms Treatment SWOT Analysis
- 9.1.6 Bayer AG Recent Developments

### 9.2 Fervent Pharmaceuticals, LLC

- 9.2.1 Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Basic Information
- 9.2.2 Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Product Overview
- 9.2.3 Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Product Market Performance
- 9.2.4 Fervent Pharmaceuticals, LLC Business Overview
- 9.2.5 Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment SWOT Analysis
- 9.2.6 Fervent Pharmaceuticals, LLC Recent Developments

### 9.3 Astellas Pharma Inc.

- 9.3.1 Astellas Pharma Inc. Vasomotor Symptoms Treatment Basic Information
- 9.3.2 Astellas Pharma Inc. Vasomotor Symptoms Treatment Product Overview
- 9.3.3 Astellas Pharma Inc. Vasomotor Symptoms Treatment Product Market Performance
- 9.3.4 Astellas Pharma Inc. Vasomotor Symptoms Treatment SWOT Analysis
- 9.3.5 Astellas Pharma Inc. Business Overview
- 9.3.6 Astellas Pharma Inc. Recent Developments

### 9.4 Frazier Healthcare Partners

- 9.4.1 Frazier Healthcare Partners Vasomotor Symptoms Treatment Basic Information
- 9.4.2 Frazier Healthcare Partners Vasomotor Symptoms Treatment Product Overview
- 9.4.3 Frazier Healthcare Partners Vasomotor Symptoms Treatment Product Market Performance
- 9.4.4 Frazier Healthcare Partners Business Overview
- 9.4.5 Frazier Healthcare Partners Recent Developments

### 9.5 Mitsubishi Tanabe Pharma Corporation

- 9.5.1 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Basic Information
- 9.5.2 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment

## Product Overview

9.5.3 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment

## Product Market Performance

9.5.4 Mitsubishi Tanabe Pharma Corporation Business Overview

9.5.5 Mitsubishi Tanabe Pharma Corporation Recent Developments

## 9.6 Eli Lilly and Company

9.6.1 Eli Lilly and Company Vasomotor Symptoms Treatment Basic Information

9.6.2 Eli Lilly and Company Vasomotor Symptoms Treatment Product Overview

9.6.3 Eli Lilly and Company Vasomotor Symptoms Treatment Product Market

## Performance

9.6.4 Eli Lilly and Company Business Overview

9.6.5 Eli Lilly and Company Recent Developments

## 9.7 AbbVie Inc.

9.7.1 AbbVie Inc. Vasomotor Symptoms Treatment Basic Information

9.7.2 AbbVie Inc. Vasomotor Symptoms Treatment Product Overview

9.7.3 AbbVie Inc. Vasomotor Symptoms Treatment Product Market Performance

9.7.4 AbbVie Inc. Business Overview

9.7.5 AbbVie Inc. Recent Developments

## 9.8 AMAG Pharmaceuticals Inc.

9.8.1 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Basic Information

9.8.2 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product Overview

9.8.3 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product Market

## Performance

9.8.4 AMAG Pharmaceuticals Inc. Business Overview

9.8.5 AMAG Pharmaceuticals Inc. Recent Developments

## 9.9 Emcure Pharmaceuticals Limited

9.9.1 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Basic Information

9.9.2 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product Overview

9.9.3 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product Market Performance

9.9.4 Emcure Pharmaceuticals Limited Business Overview

9.9.5 Emcure Pharmaceuticals Limited Recent Developments

## 9.10 Merck and Co., Inc.

9.10.1 Merck and Co., Inc. Vasomotor Symptoms Treatment Basic Information

9.10.2 Merck and Co., Inc. Vasomotor Symptoms Treatment Product Overview

9.10.3 Merck and Co., Inc. Vasomotor Symptoms Treatment Product Market

## Performance

- 9.10.4 Merck and Co., Inc. Business Overview
- 9.10.5 Merck and Co., Inc. Recent Developments
- 9.11 Novartis AG
  - 9.11.1 Novartis AG Vasomotor Symptoms Treatment Basic Information
  - 9.11.2 Novartis AG Vasomotor Symptoms Treatment Product Overview
  - 9.11.3 Novartis AG Vasomotor Symptoms Treatment Product Market Performance
  - 9.11.4 Novartis AG Business Overview
  - 9.11.5 Novartis AG Recent Developments
- 9.12 Novo Nordisk A/S
  - 9.12.1 Novo Nordisk A/S Vasomotor Symptoms Treatment Basic Information
  - 9.12.2 Novo Nordisk A/S Vasomotor Symptoms Treatment Product Overview
  - 9.12.3 Novo Nordisk A/S Vasomotor Symptoms Treatment Product Market Performance
  - 9.12.4 Novo Nordisk A/S Business Overview
  - 9.12.5 Novo Nordisk A/S Recent Developments
- 9.13 Pfizer Inc.
  - 9.13.1 Pfizer Inc. Vasomotor Symptoms Treatment Basic Information
  - 9.13.2 Pfizer Inc. Vasomotor Symptoms Treatment Product Overview
  - 9.13.3 Pfizer Inc. Vasomotor Symptoms Treatment Product Market Performance
  - 9.13.4 Pfizer Inc. Business Overview
  - 9.13.5 Pfizer Inc. Recent Developments
- 9.14 Teva Pharmaceutical Industries Ltd.
  - 9.14.1 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Basic Information
  - 9.14.2 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product Overview
  - 9.14.3 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product Market Performance
  - 9.14.4 Teva Pharmaceutical Industries Ltd. Business Overview
  - 9.14.5 Teva Pharmaceutical Industries Ltd. Recent Developments

## **10 VASOMOTOR SYMPTOMS TREATMENT MARKET FORECAST BY REGION**

- 10.1 Global Vasomotor Symptoms Treatment Market Size Forecast
- 10.2 Global Vasomotor Symptoms Treatment Market Forecast by Region
  - 10.2.1 North America Market Size Forecast by Country
  - 10.2.2 Europe Vasomotor Symptoms Treatment Market Size Forecast by Country
  - 10.2.3 Asia Pacific Vasomotor Symptoms Treatment Market Size Forecast by Region
  - 10.2.4 South America Vasomotor Symptoms Treatment Market Size Forecast by

Country

10.2.5 Middle East and Africa Forecasted Consumption of Vasomotor Symptoms Treatment by Country

## **11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)**

11.1 Global Vasomotor Symptoms Treatment Market Forecast by Type (2025-2030)

11.1.1 Global Forecasted Sales of Vasomotor Symptoms Treatment by Type (2025-2030)

11.1.2 Global Vasomotor Symptoms Treatment Market Size Forecast by Type (2025-2030)

11.1.3 Global Forecasted Price of Vasomotor Symptoms Treatment by Type (2025-2030)

11.2 Global Vasomotor Symptoms Treatment Market Forecast by Application (2025-2030)

11.2.1 Global Vasomotor Symptoms Treatment Sales (K Units) Forecast by Application

11.2.2 Global Vasomotor Symptoms Treatment Market Size (M USD) Forecast by Application (2025-2030)

## **12 CONCLUSION AND KEY FINDINGS**

## List Of Tables

### LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Vasomotor Symptoms Treatment Market Size Comparison by Region (M USD)

Table 5. Global Vasomotor Symptoms Treatment Sales (K Units) by Manufacturers (2019-2024)

Table 6. Global Vasomotor Symptoms Treatment Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Vasomotor Symptoms Treatment Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Vasomotor Symptoms Treatment Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vasomotor Symptoms Treatment as of 2022)

Table 10. Global Market Vasomotor Symptoms Treatment Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Vasomotor Symptoms Treatment Sales Sites and Area Served

Table 12. Manufacturers Vasomotor Symptoms Treatment Product Type

Table 13. Global Vasomotor Symptoms Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Vasomotor Symptoms Treatment

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Vasomotor Symptoms Treatment Market Challenges

Table 22. Global Vasomotor Symptoms Treatment Sales by Type (K Units)

Table 23. Global Vasomotor Symptoms Treatment Market Size by Type (M USD)

Table 24. Global Vasomotor Symptoms Treatment Sales (K Units) by Type (2019-2024)

Table 25. Global Vasomotor Symptoms Treatment Sales Market Share by Type (2019-2024)

Table 26. Global Vasomotor Symptoms Treatment Market Size (M USD) by Type (2019-2024)

- Table 27. Global Vasomotor Symptoms Treatment Market Size Share by Type (2019-2024)
- Table 28. Global Vasomotor Symptoms Treatment Price (USD/Unit) by Type (2019-2024)
- Table 29. Global Vasomotor Symptoms Treatment Sales (K Units) by Application
- Table 30. Global Vasomotor Symptoms Treatment Market Size by Application
- Table 31. Global Vasomotor Symptoms Treatment Sales by Application (2019-2024) & (K Units)
- Table 32. Global Vasomotor Symptoms Treatment Sales Market Share by Application (2019-2024)
- Table 33. Global Vasomotor Symptoms Treatment Sales by Application (2019-2024) & (M USD)
- Table 34. Global Vasomotor Symptoms Treatment Market Share by Application (2019-2024)
- Table 35. Global Vasomotor Symptoms Treatment Sales Growth Rate by Application (2019-2024)
- Table 36. Global Vasomotor Symptoms Treatment Sales by Region (2019-2024) & (K Units)
- Table 37. Global Vasomotor Symptoms Treatment Sales Market Share by Region (2019-2024)
- Table 38. North America Vasomotor Symptoms Treatment Sales by Country (2019-2024) & (K Units)
- Table 39. Europe Vasomotor Symptoms Treatment Sales by Country (2019-2024) & (K Units)
- Table 40. Asia Pacific Vasomotor Symptoms Treatment Sales by Region (2019-2024) & (K Units)
- Table 41. South America Vasomotor Symptoms Treatment Sales by Country (2019-2024) & (K Units)
- Table 42. Middle East and Africa Vasomotor Symptoms Treatment Sales by Region (2019-2024) & (K Units)
- Table 43. Bayer AG Vasomotor Symptoms Treatment Basic Information
- Table 44. Bayer AG Vasomotor Symptoms Treatment Product Overview
- Table 45. Bayer AG Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 46. Bayer AG Business Overview
- Table 47. Bayer AG Vasomotor Symptoms Treatment SWOT Analysis
- Table 48. Bayer AG Recent Developments
- Table 49. Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Basic Information

Table 50. Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Product Overview

Table 51. Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 52. Fervent Pharmaceuticals, LLC Business Overview

Table 53. Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment SWOT Analysis

Table 54. Fervent Pharmaceuticals, LLC Recent Developments

Table 55. Astellas Pharma Inc. Vasomotor Symptoms Treatment Basic Information

Table 56. Astellas Pharma Inc. Vasomotor Symptoms Treatment Product Overview

Table 57. Astellas Pharma Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 58. Astellas Pharma Inc. Vasomotor Symptoms Treatment SWOT Analysis

Table 59. Astellas Pharma Inc. Business Overview

Table 60. Astellas Pharma Inc. Recent Developments

Table 61. Frazier Healthcare Partners Vasomotor Symptoms Treatment Basic Information

Table 62. Frazier Healthcare Partners Vasomotor Symptoms Treatment Product Overview

Table 63. Frazier Healthcare Partners Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 64. Frazier Healthcare Partners Business Overview

Table 65. Frazier Healthcare Partners Recent Developments

Table 66. Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Basic Information

Table 67. Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Product Overview

Table 68. Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 69. Mitsubishi Tanabe Pharma Corporation Business Overview

Table 70. Mitsubishi Tanabe Pharma Corporation Recent Developments

Table 71. Eli Lilly and Company Vasomotor Symptoms Treatment Basic Information

Table 72. Eli Lilly and Company Vasomotor Symptoms Treatment Product Overview

Table 73. Eli Lilly and Company Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 74. Eli Lilly and Company Business Overview

Table 75. Eli Lilly and Company Recent Developments

Table 76. AbbVie Inc. Vasomotor Symptoms Treatment Basic Information

Table 77. AbbVie Inc. Vasomotor Symptoms Treatment Product Overview

Table 78. AbbVie Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 79. AbbVie Inc. Business Overview

Table 80. AbbVie Inc. Recent Developments

Table 81. AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Basic Information

Table 82. AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product Overview

Table 83. AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 84. AMAG Pharmaceuticals Inc. Business Overview

Table 85. AMAG Pharmaceuticals Inc. Recent Developments

Table 86. Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Basic Information

Table 87. Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product Overview

Table 88. Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 89. Emcure Pharmaceuticals Limited Business Overview

Table 90. Emcure Pharmaceuticals Limited Recent Developments

Table 91. Merck and Co., Inc. Vasomotor Symptoms Treatment Basic Information

Table 92. Merck and Co., Inc. Vasomotor Symptoms Treatment Product Overview

Table 93. Merck and Co., Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 94. Merck and Co., Inc. Business Overview

Table 95. Merck and Co., Inc. Recent Developments

Table 96. Novartis AG Vasomotor Symptoms Treatment Basic Information

Table 97. Novartis AG Vasomotor Symptoms Treatment Product Overview

Table 98. Novartis AG Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 99. Novartis AG Business Overview

Table 100. Novartis AG Recent Developments

Table 101. Novo Nordisk A/S Vasomotor Symptoms Treatment Basic Information

Table 102. Novo Nordisk A/S Vasomotor Symptoms Treatment Product Overview

Table 103. Novo Nordisk A/S Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 104. Novo Nordisk A/S Business Overview

Table 105. Novo Nordisk A/S Recent Developments

Table 106. Pfizer Inc. Vasomotor Symptoms Treatment Basic Information

Table 107. Pfizer Inc. Vasomotor Symptoms Treatment Product Overview

Table 108. Pfizer Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 109. Pfizer Inc. Business Overview

Table 110. Pfizer Inc. Recent Developments

Table 111. Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Basic Information

Table 112. Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product Overview

Table 113. Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 114. Teva Pharmaceutical Industries Ltd. Business Overview

Table 115. Teva Pharmaceutical Industries Ltd. Recent Developments

Table 116. Global Vasomotor Symptoms Treatment Sales Forecast by Region (2025-2030) & (K Units)

Table 117. Global Vasomotor Symptoms Treatment Market Size Forecast by Region (2025-2030) & (M USD)

Table 118. North America Vasomotor Symptoms Treatment Sales Forecast by Country (2025-2030) & (K Units)

Table 119. North America Vasomotor Symptoms Treatment Market Size Forecast by Country (2025-2030) & (M USD)

Table 120. Europe Vasomotor Symptoms Treatment Sales Forecast by Country (2025-2030) & (K Units)

Table 121. Europe Vasomotor Symptoms Treatment Market Size Forecast by Country (2025-2030) & (M USD)

Table 122. Asia Pacific Vasomotor Symptoms Treatment Sales Forecast by Region (2025-2030) & (K Units)

Table 123. Asia Pacific Vasomotor Symptoms Treatment Market Size Forecast by Region (2025-2030) & (M USD)

Table 124. South America Vasomotor Symptoms Treatment Sales Forecast by Country (2025-2030) & (K Units)

Table 125. South America Vasomotor Symptoms Treatment Market Size Forecast by Country (2025-2030) & (M USD)

Table 126. Middle East and Africa Vasomotor Symptoms Treatment Consumption Forecast by Country (2025-2030) & (Units)

Table 127. Middle East and Africa Vasomotor Symptoms Treatment Market Size Forecast by Country (2025-2030) & (M USD)

Table 128. Global Vasomotor Symptoms Treatment Sales Forecast by Type (2025-2030) & (K Units)

Table 129. Global Vasomotor Symptoms Treatment Market Size Forecast by Type (2025-2030) & (M USD)

Table 130. Global Vasomotor Symptoms Treatment Price Forecast by Type (2025-2030) & (USD/Unit)

Table 131. Global Vasomotor Symptoms Treatment Sales (K Units) Forecast by Application (2025-2030)

Table 132. Global Vasomotor Symptoms Treatment Market Size Forecast by Application (2025-2030) & (M USD)

## List Of Figures

### LIST OF FIGURES

Figure 1. Product Picture of Vasomotor Symptoms Treatment

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Vasomotor Symptoms Treatment Market Size (M USD), 2019-2030

Figure 5. Global Vasomotor Symptoms Treatment Market Size (M USD) (2019-2030)

Figure 6. Global Vasomotor Symptoms Treatment Sales (K Units) & (2019-2030)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Vasomotor Symptoms Treatment Market Size by Country (M USD)

Figure 11. Vasomotor Symptoms Treatment Sales Share by Manufacturers in 2023

Figure 12. Global Vasomotor Symptoms Treatment Revenue Share by Manufacturers in 2023

Figure 13. Vasomotor Symptoms Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Vasomotor Symptoms Treatment Average Price (USD/Unit) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Vasomotor Symptoms Treatment Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Vasomotor Symptoms Treatment Market Share by Type

Figure 18. Sales Market Share of Vasomotor Symptoms Treatment by Type (2019-2024)

Figure 19. Sales Market Share of Vasomotor Symptoms Treatment by Type in 2023

Figure 20. Market Size Share of Vasomotor Symptoms Treatment by Type (2019-2024)

Figure 21. Market Size Market Share of Vasomotor Symptoms Treatment by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Vasomotor Symptoms Treatment Market Share by Application

Figure 24. Global Vasomotor Symptoms Treatment Sales Market Share by Application (2019-2024)

Figure 25. Global Vasomotor Symptoms Treatment Sales Market Share by Application in 2023

Figure 26. Global Vasomotor Symptoms Treatment Market Share by Application (2019-2024)

Figure 27. Global Vasomotor Symptoms Treatment Market Share by Application in 2023

Figure 28. Global Vasomotor Symptoms Treatment Sales Growth Rate by Application (2019-2024)

Figure 29. Global Vasomotor Symptoms Treatment Sales Market Share by Region (2019-2024)

Figure 30. North America Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 31. North America Vasomotor Symptoms Treatment Sales Market Share by Country in 2023

Figure 32. U.S. Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 33. Canada Vasomotor Symptoms Treatment Sales (K Units) and Growth Rate (2019-2024)

Figure 34. Mexico Vasomotor Symptoms Treatment Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 36. Europe Vasomotor Symptoms Treatment Sales Market Share by Country in 2023

Figure 37. Germany Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 38. France Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 39. U.K. Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 40. Italy Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 41. Russia Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 42. Asia Pacific Vasomotor Symptoms Treatment Sales and Growth Rate (K Units)

Figure 43. Asia Pacific Vasomotor Symptoms Treatment Sales Market Share by Region in 2023

Figure 44. China Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 45. Japan Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 46. South Korea Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 47. India Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 48. Southeast Asia Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Vasomotor Symptoms Treatment Sales and Growth Rate (K Units)

Figure 50. South America Vasomotor Symptoms Treatment Sales Market Share by Country in 2023

Figure 51. Brazil Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Vasomotor Symptoms Treatment Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Vasomotor Symptoms Treatment Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Vasomotor Symptoms Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global Vasomotor Symptoms Treatment Sales Forecast by Volume (2019-2030) & (K Units)

Figure 62. Global Vasomotor Symptoms Treatment Market Size Forecast by Value (2019-2030) & (M USD)

Figure 63. Global Vasomotor Symptoms Treatment Sales Market Share Forecast by Type (2025-2030)

Figure 64. Global Vasomotor Symptoms Treatment Market Share Forecast by Type (2025-2030)

Figure 65. Global Vasomotor Symptoms Treatment Sales Forecast by Application (2025-2030)

Figure 66. Global Vasomotor Symptoms Treatment Market Share Forecast by

Application (2025-2030)

## I would like to order

Product name: Global Vasomotor Symptoms Treatment Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/GB3FB2364790EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB3FB2364790EN.html>